Itau Unibanco Holding S.A. Editas Medicine, Inc. Transaction History

Itau Unibanco Holding S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $3,081 - $5,477	-493 Reduced 18.9%	2,116 $21,000
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $4,435 - $5,967	641 Added 32.57%	2,609 $20,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $12,516 - $22,572	1,968 New	1,968 $16,000
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $3,886 - $8,305	-389 Reduced 91.75%	35 $0
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $506 - $994	36 Added 9.28%	424 $8,000
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $10,301 - $15,741	388 New	388 $11,000

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.1M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

Stay updated on Itau Unibanco Holding S.A. with notifications on news.